Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年 创立，公司目前正布局多款癌症实验性疗法研发管线。 来源：智通财经网 生物医药公司Eikon Therapeutics(EIKN.US)周三表示，其美国首次公开发行(IPO)募资3.812亿美元，共发 行约2120万股普通股，发行价定为每股18美元。此次发行价位于该公司16至18美元目标区间上限。 据了解，本次上市计划进行之际，美国IPO市场在2026年已显现回暖迹象。去年10月的政府停摆曾导致 多家企业推迟上市计划。而今年初，生物科技企业IPO同样迎来复苏，SpyGlass Pharma(SGP.US)、 AgomAb Therapeutics(AGMB.US)等生物医药研发企业均已在1月递交美国上市申请。 公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期 临床试验，该研究的中期分析数据预计将于2026年下半年公布。 Eikon Therapeutics的股票将于周四在纳斯达克挂牌 ...

Eikon Therapeutics的股票将于周四在纳斯达克挂牌交易，股票代码为"EIKN"。本次IPO的承销商包括摩 根大通、摩根士丹利、美国银行证券、Cantor及瑞穗证券。 Eikon Therapeutics由诺贝尔化学奖得主Eric Betzig、Xavier Darzacq、Luke Lavis和Robert Tjian于2019年 创立，公司目前正布局多款癌症实验性疗法研发管线。 公司研发进度最快的候选药物EIK1001，正与默沙东(MRK.US)的Keytruda联合开展一款皮肤癌的中后期 临床试验，该研究的中期分析数据预计将于2026年下半年公布。 生物医药公司Eikon Therapeutics(EIKN.US)周三表示，其美国首次公开发行(IPO)募资3.812亿美元，共发 行约2120万股普通股，发行价定为每股18美元。此次发行价位于该公司16至18美元目标区间上限。 据了解，本次上市计划进行之际，美国IPO市场在2026年已显现回暖迹象。去年10月的政府停摆曾导致 多家企业推迟上市计划。而今年初，生物科技企业IPO同样迎来复苏，SpyGlass Pharma(SGP.US)、 Ago ...

2026年伊始，长三角铁路建设交出亮眼"成绩单"。截至2025年底，区域铁路营业里程突破1.54万公里， 其中高铁里程攀升至8100余公里。作为长三角轨道交通网络的关键一环，沪苏湖高铁开通一周年以来， 累计安全运送旅客超3360万人次，日行列车从最初80对增至111.5对。这条将上海与湖州通行时间压缩 至半小时的"黄金走廊"，不仅让"工作在上海，生活在湖州"的同城化图景照进现实，更打通了研发实验 室与工厂生产线的"极速对流"通道。 就在这个月，沪苏浙皖四地同步亮出产业转型"施工图"：上海印发《支持先进制造业转型升级三年行动 方案（2026-2028年）》，苏、浙、皖则分别实施"人工智能+"行动、未来产业"星火计划"和智能机器人 专项。轨道交通的物理连接，正将四地政策规划焊接成一张紧密的产业协同网。 这种"时间折叠"效应，对于从实验室"0到1"走向生产线"1到10"的成果转化尤为关键。工艺参数的着 陆、试制的反复迭代、质量问题的现场闭环，绝非简单的图纸交接，而是充满了不确定性。视频会议或 许能高效传递信息，但永远无法替代研发专家与一线技工在产线的机器轰鸣声中的"即时碰撞"，当场解 决问题的"在场感"。 当"必须 ...

在全球肿瘤治疗进入精准医疗时代的背景下，个性化免疫疗法成为突破传统治疗瓶颈的核心方向。立康生命科技成立于2017年，扎根北京经济技术开发区， 是一家专注于个性化肿瘤疫苗和T细胞药物研发的创新型生物医药企业。作为国家高新技术企业、北京市"专精特新"企业，公司以"开发First in Class的免疫 细胞药物"为宗旨，汇聚国内外顶尖科研与产业人才，研发人员占比高达84%，凭借自主知识产权的核心技术平台，在肿瘤精准免疫治疗领域持续突破，先 后入围德勤中国医药健康明日之星、毕马威生物科创领航50等权威榜单。 陈贝倪/文 免责声明：本文观点仅代表作者本人，供参考、交流，不构成任何建议。 收藏 著提升了安全性与耐受性。其核心技术依托肿瘤新抗原分析生物信息学平台（LNEA）、高通量抗原/T细胞筛选平台，结合AI技术实现个性化靶点精准筛 选，形成全链路技术闭环。 自研发以来，LK101注射液已取得一系列突破性成果。在监管批准方面，产品于2023年3月获得国家药品监督管理局（NMPA）首款AI+个性化靶点mRNA肿 瘤疫苗IND临床批件；2025年2月获美国食品药品管理局（FDA）IND批准，成为中国首款且目前唯一获FDA批 ...

□ 日前，江苏省首单"专利产业化+认股权"模式成功落地，南京生物医药分中心持有的凝霁生物认股权 在江苏股权交易中心认股权综合服务平台完成登记托管 发挥制度优势疏通企业上市通道 2025年10月17日，睿龙材料科技无锡股份有限公司（下称"睿龙科技"）挂牌新三板。2026年1月8日，睿 龙科技北交所IPO辅导机构国泰海通发布第八期辅导进展报告。 睿龙科技是射频微波材料和封装材料生产商，在2024年10月被江苏股权交易中心纳入"专精特新"专板培 育。短短一年有余，睿龙科技在多层次资本市场中逐级而上，凸显了上市企业培育的"江苏速度"。 作为江苏股权交易中心服务的全国首家"绿色通道+直联审核"机制适用企业，睿龙科技的新三板挂牌申 请，在申报当天便获得受理，相隔1个工作日即发出首轮问询，34个交易日在新三板创新层迅速过会。 江苏股权交易中心企业服务中心相关负责人表示，在睿龙科技的培育过程中，江苏股权交易中心充分发 挥相关制度优势，联合辅导机构与企业深入沟通协调，并制定专项服务措施，帮助企业制定了高效清晰 的上市路径。 □ 南京生物医药分中心以早期项目转化启动资金，在凝霁生物小分子创新药物从概念验证到申报上市的 关键阶段， ...

"当时全球没有企业把它开发成产品。"基因启明创始人、董事长冯纪开说，"我们算是第一个系统做这 件事的。"选择这条路径，意味着放弃了当时更热门的赛道，踏入了一个充满未知的产业化地带。它的 研发过程没有惊心动魄的转折，更像是一场与时间、技术与耐心的漫长对峙。这场对峙得以持续，离不 开其身后那片被称为"中国药谷"的产业土壤。而站在城市产业发展的视角审视，基因启明的这场探索实 践，恰是北京生物医药产业迈向"前沿创新"的生动微观样本。 攻克免疫细胞技术无人区 【编者按】 新质生产力加速成长、产业升级步履铿锵、首都功能不断提升 "十四五"时期，我们见证了 北京高质量发展的坚实步伐。带着超5.2万亿地区生产总值的底气，这座城市开启了"十五五"的新征 程。值此2026北京"两会"之际，我们推出"乘风'十五五' 北京的领与先"系列专题报道，聚焦北京在科技 创新、产业跃升、城市治理、民生改善等各领域的先行探索与引领实践，擘画高质量发展新图景的思路 与举措。 在北京大兴生物医药基地的一间实验室里，技术人员正通过显微镜观察一种稀有免疫细胞的生长状态。 这种细胞名为iNKT，它在人体内数量极少，却是基因启明公司过去近十年研发工作的全部 ...

Core Viewpoint - The research led by Academician Yan Ning and his team successfully captured the open-state structure of the human Nav1.7 sodium channel, providing critical insights into pain mechanisms and potential analgesic drug development [2][3]. Group 1: Sodium Channel Function and Importance - Voltage-gated sodium channels (Nav) are essential transmembrane proteins that generate and transmit biological electrical signals, controlling key physiological processes such as neurotransmitter release and muscle contraction [6]. - Abnormalities in sodium channel function are closely related to various severe diseases, including epilepsy, arrhythmias, and chronic pain, with over a thousand pathogenic mutations identified in human sodium channel proteins [6][9]. - The rapid inactivation characteristic of sodium channels, which occurs within milliseconds, is crucial for ensuring the "all-or-nothing" principle of action potentials and unidirectional conduction [6]. Group 2: Research Methodology and Findings - The research team utilized veratridine (VTD), a potent sodium channel opener, to stabilize and capture the open state of Nav1.7, overcoming the challenge of capturing this transient state [8]. - Experiments demonstrated that VTD induced a dual regulatory effect on Nav1.7, inhibiting peak current while promoting sustained and tail currents [9]. - The study identified two distinct conformations of Nav1.7, with one showing a pore diameter of 8.2 Å, larger than the hydrated sodium ion diameter, confirming the channel's open state [9]. Group 3: Molecular Mechanism of Fast Inactivation - The research proposed a "wedge model" for the rapid inactivation of sodium channels, explaining how specific structural changes lead to the blocking of ion flow [14]. - The study revealed that mutations associated with sodium channel-related diseases cluster in specific regions, affecting the interaction and conformational coupling necessary for rapid inactivation [15]. Group 4: Implications for Drug Development - The high-resolution structure of Nav1.7 in its open state is significant for the development of analgesic drugs targeting this channel, which is a key focus in drug research for neurological and cardiovascular diseases [17]. - Sodium channels are critical targets for local anesthetics, anti-epileptic drugs, and analgesics, with the ability to selectively bind to specific channel states enhancing therapeutic efficacy and reducing side effects [17].

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight increase in stock price and notable changes in financing activities on January 27, with a net financing outflow [1] - On January 27, He Yuan Bio's stock rose by 0.85%, with a trading volume of 217 million yuan, and a financing buy-in amount of 16.12 million yuan, while the financing repayment was 25.13 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of January 27, the total balance of margin trading for He Yuan Bio was 262 million yuan, which represents 7.72% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1: Market Overview - The three major A-share indices collectively rose today, with the Shanghai Composite Index up 0.18% closing at 4139.90 points, the Shenzhen Component Index up 0.09% at 14329.91 points, and the ChiNext Index up 0.71% at 3342.60 points [2] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets was 29,215 billion yuan, a decrease of 3,592 billion yuan from the previous day, with over 1,900 stocks in the three markets showing gains [2] Group 2: Semiconductor Industry - The semiconductor industry chain showed active performance today, particularly in the storage chip and semiconductor equipment sectors, with stocks like Dongxin Co. hitting the daily limit and others like Purun Co. and Jingzhida rising significantly [4] - Analysts from multiple brokerage firms noted that Samsung Electronics plans to raise NAND flash supply prices by over 100% in Q1 2026, exceeding market expectations [6] - Micron Technology announced a $24 billion investment in a NAND flash factory in Singapore over the next decade, with production expected to start in the second half of 2028, creating 3,000 jobs [7] - The storage product prices are expected to continue rising in Q1 and Q2 of 2026, driven by strong AI demand and supply constraints, benefiting various segments of the domestic storage industry [7] Group 3: Precious Metals - The precious metals sector continued to rise, with Zijin Mining's stock price increasing significantly after announcing an acquisition of Allied Gold Corporation for approximately 5.5 billion Canadian dollars (about 28 billion yuan) [9][13] - Zijin Mining's acquisition includes core assets such as the Sadiola gold mine and the Kurmuk gold mine, with expected gold production increasing significantly by 2029 [13] - Morgan Stanley maintained a target price of 48 HKD for Zijin Mining's H-shares and 45 RMB for its A-shares, rating it as "overweight" due to positive production growth outlooks [14] Group 4: Influenza Sector - The influenza sector was active following a recent surge, with companies involved in vaccines, testing reagents, and raw materials benefiting from increased attention [19] - The stock of Wangshan Wangshui surged over 10% today, reflecting the market's response to the recent outbreak of the Nipah virus in India, which has led to heightened demand for related medical products [21]

消息面上，君实生物发布公告称，公司已完成发行2026年度第一期科技创新债券，发行总额为人民币10 亿元，期限为3+2年，于2031年1月26日到期，发行利率为2.70%，募集资金预计将主要用于公司核心的 药物研发、科技创新及相关业务拓展，有助于进一步巩固其在生物医药领域的研发实力和市场竞争力， 符合其作为科技创新企业的战略发展需求。 君实生物(01877)再涨超5%，截至发稿，涨4.55%，报24.84港元，成交额1.79亿港元。 ...